Global HLA Typing Transplant Diagnostics Services Market is expected to reach USD 1,053.20 million by 2025 from USD 532.5million in 2017, at a CAGR of 9.0% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
The global HLA typing transplant diagnostics services market highly concentrated to a few big players and rest to local players who cater to domestic markets only. One Lambda (Thermo Fisher Scientific, Inc.) dominated the HLA typing transplant diagnostics services market accounting for a highest market share in 2017, followed by followed by Laboratory Corporation of America Holdings. Other players in this market include are Proimmune Ltd., Creative Biolabs, Histogenetics LLC, The UCLA Immunogenetics Center, Admera Health, Quick Biology, New York Blood Center, The Sequencing Center, and BloodCenter of Wisconsin, among others.
One Lambda (Thermo Fisher Scientific, Inc.):
Founded in 1956 and headquartered at Massachusetts, U.S. The company operates through four business segments, namely, Laboratory Products and Services, Life Sciences and Solutions, Analytical Instruments and Speciality Diagnostic. Life Sciences Solutions provides broad portfolio of instruments, reagents and consumables used in medical research and biological discovery, production of vaccines, and new drugs along with diagnosis of diseases. Analytical Instruments segment provides a broad offering of consumables, instruments, software and services that are used for a range of applications in the laboratory, on the production line and in the field. Specialty Diagnostics segment provides a wide range of diagnostic test kits, reagents, instruments and associated products used to increase the speed and accuracy of diagnosis.
In July 2012, One Lambda was acquired by Thermo Fisher Scientific. The company is operating as a brand of Thermo Fisher Scientific. One Lambda manufactures, designs and commercializes the histocompatibility reagents and semi-automated laboratory equipment. These are used in hospitals, institutions and research centers, which are involved in human organ transplantation and paternity testing.
Thermo Fisher Scientific Inc. has operating companies across the United States, Europe, Western Hemisphere, Africa, and Asia-Pacific. Some of its subsidiaries Thermo Electron Australia Pty Limited (Australia), Thermo Electron Holdings SAS(France), Thermo Finland Holdings LLC (Delaware), Kendro Laboratory Products (H.K.) Limited (Hong kong), Niton Europe GmbH (Germany), Thermo Ramsey S.A.(Spain) etc.
Laboratory Corporation of America Holdings:
Incorporated in 1971 and headquartered at North Carolina, U.S. Laboratory Corporation of America Holdings is a company, which is one of the leaders in the life sciences company for offering patient care, provides clinical laboratory and end-to-end drug development services. The company operates through two business segments namely LabCorp diagnostics and Covance drug development. The LabCorp Diagnostics offers wide range of testing products an integrated network of primary and specialty laboratories across the U.S., and Covance drug development is engaged in an end-to-end drug development services including the early-stage research to regulatory approval and beyond.
The company has its major presence in U.S., Canada, UK, and Switzerland. The company also operates in 60 countries globally.
U.S. HLA Typing Transplant Diagnostics Services Market – Industry Trends and Forecast to 2024
Global HLA Typing Transplant Diagnostics Services Market – Industry Trends and Forecast to 2025
North America HLA Typing Transplant Diagnostics Services Market – Industry Trends and Forecast to 2025
Europe HLA Typing Transplant Diagnostics Services Market – Industry Trends and Forecast to 2025
Asia-Pacific HLA Typing Transplant Diagnostics Services Market – Industry Trends and Forecast to 2025